the Commonwealth of Puerto Rico and U.S. territories, and local level sub-grant recipients.

ANNUAL BURDEN ESTIMATES

Information collection	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
CSBG State Plan	56	1	18	1,008
CSBG Eligible Entity List	56	1	2	112
Estimated Total Annual Burden Hours for CSBG Grant Recipients	.....	.....	.....	1,064
	1,000	0.33	0.15	16.5
Estimated Total Annual Burden Hours for CSBG sub-grant recipients	.....	.....	.....	16.5
Estimated Total Annual Burden Hours for ALL respondents	.....	.....	.....	1,136.5

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: Section 676, Pub. L. 105–285, 112 Stat. 2735 (42 U.S.C. 9908)

Samantha L. Illangasekare,

ACF/OPRE Certifying Officer.

[FR Doc. 2026–23369 Filed 11–16–26; 8:45 am]

BILLING CODE 4184–27–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Office of Management and Budget #: 0970–0152]

Proposed Information Collection Activity; Interstate Administrative Subpoena and Notice of Lien

AGENCY: Office of Child Support Enforcement, Administration for Children and Families, Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), Department of Health and Human Services (HHS), is requesting a 3-year extension of the Interstate Administrative Subpoena and Notice of Lien (Office of Management and Budget (OMB) #: 0970–0152, expiration April 30, 2027). Minor changes are proposed to the burden hours calculation for the Notice of Lien form.

DATES: Comments due January 19, 2027.

ADDRESSES: In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above. You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov.* Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The Administrative Subpoena is used by state child support agencies to obtain income and other financial information regarding noncustodial parents for purposes of establishing, enforcing, and modifying child support orders. The Notice of Lien imposes liens in cases with overdue support and allows a state child support agency to file liens across state lines, when it is more efficient than involving the other state's child support agency.

Section 452(a)(11) of the Social Security Act requires the HHS Secretary to promulgate forms for administrative subpoenas and imposition of liens used by state child support agencies in interstate cases. Section 454(9)(E) of the Social Security Act requires each state to cooperate with any other state in using the federal forms for issuance of administrative subpoenas and imposition of liens in interstate child support cases.

Respondents: State, local, or tribal agencies administering a child support program under title IV–D of the Social Security Act.

Annual Burden Estimates: Annual burden estimates for the notice of lien have been reduced by 5 minutes since the most recent full OMB review and approval process in 2024. This reduction is due to advancements in automation and state child support system modernization. Most state child support systems now auto-populate majority of the information required for this form.

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
Administrative Subpoena	54	377	.5	10,179
Notice of Lien	54	24,633	.42	558,676

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
Estimated Total Annual Burden Hours				568,855

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

(Authority: 42 U.S.C. 652; 42 U.S.C. 654)

Samantha L. Illangasekare,

ACF/OPRE Certifying Officer.

[FR Doc. 2026–23347 Filed 11–16–26; 8:45 am]

BILLING CODE 4184–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–P–2305]

Determination That M.V.I. ADULT (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that M.V.I. ADULT (ascorbic acid 200 milligrams (mg)/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial, for injection, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Molly Arndt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6281, Silver Spring, MD 20993–0002, *Molly.Arndt@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ''Approved Drug Products With Therapeutic Equivalence Evaluations,'' which is known generally as the ''Orange Book.'' Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, is the subject of NDA 021625, held by Hospira, Inc., and initially approved on January 30, 2004. M.V.I. ADULT is indicated for prevention of vitamin deficiency in adults and pediatric patients aged 11 years and above receiving parenteral nutrition.

In a letter dated September 29, 2021, Hospira, Inc. notified FDA that M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, was being discontinued, and FDA moved the drug product to the ''Discontinued Drug Product List'' section of the Orange Book. In a letter dated January 17, 2025, Hospira Inc. requested withdrawal of NDA 021625 for M.V.I. ADULT (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5′-phosphate sodium; thiamine hydrochloride; vitamin A; vitamin E; vitamin K). In the **Federal Register** of August 4, 2025 (90 FR 36440), FDA announced that it was withdrawing approval of NDA 021625, effective September 3, 2025.

Apotex, Inc. submitted a citizen petition dated March 4, 2026 (Docket No. FDA–2026–P–2305), under 21 CFR 10.30, requesting that the Agency determine whether M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial;